{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:56:40Z","timestamp":1781146600490,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02675-w","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:54:13Z","timestamp":1777276453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA\/TCR\/BCR sequencing"],"prefix":"10.1186","volume":"25","author":[{"given":"Xianglin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"5","key":"2675_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC, Bray F. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495\u2013503.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2675_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jaad.2024.09.035","volume":"92","author":"Y Sun","year":"2025","unstructured":"Sun Y, Shen Y, Liu Q, Zhang H, Jia L, Chai Y, Jiang H, Wu M, Li Y. Global trends in melanoma burden: A comprehensive analysis from the Global Burden of Disease Study, 1990\u20132021. J Am Acad Dermatol. 2025;92(1):100\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2675_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","volume":"72","author":"SY Kim","year":"2015","unstructured":"Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol. 2015;72(6):1036\u2013e10461032.","journal-title":"J Am Acad Dermatol"},{"key":"2675_CR4","doi-asserted-by":"publisher","first-page":"680407","DOI":"10.3389\/fimmu.2021.680407","volume":"12","author":"L Mao","year":"2021","unstructured":"Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol. 2021;12:680407.","journal-title":"Front Immunol"},{"issue":"19","key":"2675_CR5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"issue":"19","key":"2675_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"6","key":"2675_CR7","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392.","journal-title":"CA Cancer J Clin"},{"key":"2675_CR8","doi-asserted-by":"publisher","first-page":"749064","DOI":"10.3389\/fonc.2021.749064","volume":"11","author":"ML Bastacky","year":"2021","unstructured":"Bastacky ML, Wang H, Fortman D, Rahman Z, Mascara GP, Brenner T, Najjar YG, Luke JJ, Kirkwood JM, Zarour HM, et al. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Front Oncol. 2021;11:749064.","journal-title":"Front Oncol"},{"issue":"1","key":"2675_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19(1):15.","journal-title":"Genome Biol"},{"issue":"12","key":"2675_CR10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh PR, Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16(12):1289\u201396.","journal-title":"Nat Methods"},{"issue":"1","key":"2675_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13059-020-1950-6","volume":"21","author":"S Yang","year":"2020","unstructured":"Yang S, Corbett SE, Koga Y, Wang Z, Johnson WE, Yajima M, Campbell JD. Decontamination of ambient RNA in single-cell RNA-seq with DecontX. Genome Biol. 2020;21(1):57.","journal-title":"Genome Biol"},{"issue":"4","key":"2675_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 2019;8(4):329\u2013e337324.","journal-title":"Cell Syst"},{"issue":"9","key":"2675_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41587-021-00896-6","volume":"39","author":"A Cortal","year":"2021","unstructured":"Cortal A, Martignetti L, Six E, Rausell A. Gene signature extraction and cell identity recognition at the single-cell level with Cell-ID. Nat Biotechnol. 2021;39(9):1095\u2013102.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2675_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284\u20137.","journal-title":"Omics"},{"key":"2675_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"2675_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, Trapnell C. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14(10):979\u201382.","journal-title":"Nat Methods"},{"issue":"7719","key":"2675_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-018-0414-6","volume":"560","author":"G La Manno","year":"2018","unstructured":"La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K, Kastriti ME, L\u00f6nnerberg P, Furlan A, et al. RNA velocity of single cells. Nature. 2018;560(7719):494\u20138.","journal-title":"Nature"},{"issue":"10","key":"2675_CR18","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1093\/bioinformatics\/btaa099","volume":"36","author":"EY Cao","year":"2020","unstructured":"Cao EY, Ouyang JF, Rackham OJL. GeneSwitches: ordering gene expression and functional events in single-cell experiments. Bioinformatics. 2020;36(10):3273\u20135.","journal-title":"Bioinformatics"},{"key":"2675_CR19","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta M, Carmona SJ. UCell: Robust and scalable single-cell gene signature scoring. Comput Struct Biotechnol J. 2021;19:3796\u20138.","journal-title":"Comput Struct Biotechnol J"},{"issue":"7","key":"2675_CR20","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41596-020-0336-2","volume":"15","author":"B Van de Sande","year":"2020","unstructured":"Van de Sande B, Flerin C, Davie K, De Waegeneer M, Hulselmans G, Aibar S, Seurinck R, Saelens W, Cannoodt R, Rouchon Q, et al. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat Protoc. 2020;15(7):2247\u201376.","journal-title":"Nat Protoc"},{"issue":"4","key":"2675_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc. 2020;15(4):1484\u2013506.","journal-title":"Nat Protoc"},{"issue":"6","key":"2675_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, Tonea R, Ovcinnikovs V, Lloyd K, Schuurman J, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42(6):1032\u2013e10501010.","journal-title":"Cancer Cell"},{"issue":"12","key":"2675_CR23","doi-asserted-by":"publisher","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","volume":"8","author":"T Walle","year":"2022","unstructured":"Walle T, Kraske JA, Liao B, Lenoir B, Timke C, von Bohlen Und Halbach E, Tran F, Griebel P, Albrecht D, Ahmed A, et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv. 2022;8(12):eabh4050.","journal-title":"Sci Adv"},{"key":"2675_CR24","doi-asserted-by":"publisher","first-page":"598877","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1\/PD-L1 Pathways: Challenges and Opportunities. Front Immunol. 2020;11:598877.","journal-title":"Front Immunol"},{"issue":"9","key":"2675_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385.","journal-title":"Exp Mol Med"},{"issue":"14","key":"2675_CR26","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO-24-02219","volume":"43","author":"SA Weiss","year":"2025","unstructured":"Weiss SA, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani NI, Hegde U, Cohen J, et al. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. J Clin Oncol. 2025;43(14):1685\u201394.","journal-title":"J Clin Oncol"},{"key":"2675_CR27","doi-asserted-by":"crossref","unstructured":"Zhao L, Ren Y, Zhang G, Zheng K, Wang J, Sha H, Zhao M, Huang R, Kang D, Su X et al. Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. J Immunother Cancer. 2024;12(6):e008611.","DOI":"10.1136\/jitc-2023-008611"},{"issue":"7","key":"2675_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632\u201342.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2675_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-014-0040-2","volume":"2","author":"M Nishino","year":"2014","unstructured":"Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014;2(1):40.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2675_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ. Toripalimab: First Global Approval. Drugs. 2019;79(5):573\u20138.","journal-title":"Drugs"},{"issue":"8","key":"2675_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14712598.2020.1762561","volume":"20","author":"B Tang","year":"2020","unstructured":"Tang B, Chi Z, Guo J. Toripalimab for the treatment of melanoma. Expert Opin Biol Ther. 2020;20(8):863\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2675_CR32","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1093\/oncolo\/oyae045","volume":"29","author":"B Tang","year":"2024","unstructured":"Tang B, Duan R, Zhang X, Qin S, Wu D, Chen J, Yao H, Chi Z, Guo J, Yan X. Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. Oncologist. 2024;29(6):e822\u20137.","journal-title":"Oncologist"},{"issue":"3","key":"2675_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamaoncol.2025.5751","volume":"12","author":"X Sheng","year":"2026","unstructured":"Sheng X, Huang G, Fang M, Li K, Wu D, Zhang X, Chen J, Zhu D, Chen Y, Li H, et al. Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial. JAMA Oncol. 2026;12(3):243\u201350.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2675_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40487-017-0055-1","volume":"6","author":"K Li","year":"2018","unstructured":"Li K, Shi M, Qin S. Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment. Oncol Ther. 2018;6(1):21\u201343.","journal-title":"Oncol Ther"},{"issue":"4","key":"2675_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2133.2006.07724.x","volume":"156","author":"P Kurschat","year":"2007","unstructured":"Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol. 2007;156(4):653\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2675_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.canlet.2015.01.012","volume":"359","author":"L Xiao","year":"2015","unstructured":"Xiao L, Yang S, Hao J, Yuan X, Luo W, Jiang L, Hu Y, Fu Z, Zhang Y, Zou C. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett. 2015;359(1):148\u201354.","journal-title":"Cancer Lett"},{"issue":"7","key":"2675_CR37","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2013.79","volume":"21","author":"C Cui","year":"2013","unstructured":"Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, Li S, Lian B, Gu K, Tao M, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther. 2013;21(7):1456\u201363.","journal-title":"Mol Ther"},{"key":"2675_CR38","doi-asserted-by":"crossref","unstructured":"Li T, Xu Y, Sun W, Yan W, Wang C, Hu T, Zhang X, Luo Z, Liu X, Chen Y. Adjuvant anti-PD-1 immunotherapy versus conventional therapy for stage III melanoma: a real-world retrospective cohort study. Pharmaceuticals (Basel). 2022;16(1):41.","DOI":"10.3390\/ph16010041"},{"key":"2675_CR39","doi-asserted-by":"publisher","first-page":"109746","DOI":"10.1016\/j.biopha.2019.109746","volume":"125","author":"J Wu","year":"2020","unstructured":"Wu J, Zhao X, Sun Q, Jiang Y, Zhang W, Luo J, Li Y. Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother. 2020;125:109746.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2675_CR40","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","volume":"28","author":"J Li","year":"2022","unstructured":"Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, et al. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022;28(10):2131\u201346.","journal-title":"Clin Cancer Res"},{"key":"2675_CR41","doi-asserted-by":"crossref","unstructured":"Fife C, Williams J, James F, Gregory S, Andreou T, Sunderland A, McKimmie C, Brownlie RJ, Salmond RJ, Heaton S et al. Natural killer cells are required for the recruitment of CD8\u2009+\u2009T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases. J Immunother Cancer. 2024;12(11):e009522.","DOI":"10.1136\/jitc-2024-009522"},{"key":"2675_CR42","doi-asserted-by":"publisher","first-page":"679117","DOI":"10.3389\/fimmu.2021.679117","volume":"12","author":"KA Shaver","year":"2021","unstructured":"Shaver KA, Croom-Perez TJ, Copik AJ. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Front Immunol. 2021;12:679117.","journal-title":"Front Immunol"},{"issue":"4","key":"2675_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14712598.2017.1289169","volume":"17","author":"M Sanlorenzo","year":"2017","unstructured":"Sanlorenzo M, Vujic I, Carnevale-Schianca F, Quaglino P, Gammaitoni L, Fierro MT, Aglietta M, Sangiolo D. Role of interferon in melanoma: old hopes and new perspectives. Expert Opin Biol Ther. 2017;17(4):475\u201383.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2675_CR44","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/2159-8290.CD-NB2023-0019","volume":"13","author":"TCR Diversity Underpins Immunotherapy Success","year":"2023","unstructured":"TCR Diversity Underpins Immunotherapy Success. Cancer Discov. 2023;13(5):1031\u20132.","journal-title":"Cancer Discov"},{"issue":"1","key":"2675_CR45","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-021-24343-x","volume":"12","author":"S Valpione","year":"2021","unstructured":"Valpione S, Mundra PA, Galvani E, Campana LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N, et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun. 2021;12(1):4098.","journal-title":"Nat Commun"},{"issue":"7791","key":"2675_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135.","journal-title":"Nature"},{"issue":"11\u201312","key":"2675_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s00335-018-9778-z","volume":"29","author":"J Da Gama Duarte","year":"2018","unstructured":"Da Gama Duarte J, Peyper JM, Blackburn JM. B cells and antibody production in melanoma. Mamm Genome. 2018;29(11\u201312):790\u2013805.","journal-title":"Mamm Genome"},{"issue":"18","key":"2675_CR48","doi-asserted-by":"publisher","first-page":"e2501269122","DOI":"10.1073\/pnas.2501269122","volume":"122","author":"Y Che","year":"2025","unstructured":"Che Y, Lee J, Abou-Taleb F, Rieger KE, Satpathy AT, Chang ALS, Chang HY. Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response. Proc Natl Acad Sci U S A. 2025;122(18):e2501269122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2675_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13073-019-0647-5","volume":"11","author":"SR Selitsky","year":"2019","unstructured":"Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, Moschos SJ, Parker JS, Vincent BG. Prognostic value of B cells in cutaneous melanoma. Genome Med. 2019;11(1):36.","journal-title":"Genome Med"},{"key":"2675_CR50","doi-asserted-by":"crossref","unstructured":"Dou A, Fang J. Heterogeneous myeloid cells in tumors. Cancers (Basel). 2021;13(15):3772.","DOI":"10.3390\/cancers13153772"},{"issue":"1","key":"2675_CR51","doi-asserted-by":"publisher","first-page":"1786888","DOI":"10.1080\/2162402X.2020.1786888","volume":"9","author":"Y Pico de Coa\u00f1a","year":"2020","unstructured":"Pico de Coa\u00f1a Y, Wolodarski M, van der Haar \u00c0vila I, Nakajima T, Rentouli S, Lundqvist A, Masucci G, Hansson J, Kiessling R. PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. Oncoimmunology. 2020;9(1):1786888.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2675_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cncr.32506","volume":"126","author":"EK Bartlett","year":"2020","unstructured":"Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, Coit DG, Ariyan CE. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76\u201385.","journal-title":"Cancer"},{"issue":"1","key":"2675_CR53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2675_CR54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s43018-021-00180-1","volume":"2","author":"J Han","year":"2021","unstructured":"Han J, Zhao Y, Shirai K, Molodtsov A, Kolling FW, Fisher JL, Zhang P, Yan S, Searles TG, Bader JM, et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer. 2021;2(3):300\u201311.","journal-title":"Nat Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02675-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02675-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02675-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:02:23Z","timestamp":1781143343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02675-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02675-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the ethics committee of Fudan University Shanghai Cancer Center, Shanghai, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}